May 30, 2026
6 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CHICAGO — Treating resected brain metastases with cesium-131 tile-based radiation therapy immediately after surgery significantly improved local recurrence and survival compared with standard of care.The findings from a phase 3 randomized trial, presented at ASCO Annual Meeting, showed patients who received the tile therapy had a 93% improvement in surgical bed recurrence and a 41%
May 30, 2026
6 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Tile-Based Radiation Tops Standard for Resected Brain Metastases

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases

Nuove cure contro i tumori, ma è rebus sugli effetti collaterali

Five highlights from lung-cancer research

A new sensor could enable earlier detection of bladder cancer

Cancro al cervello: scoperta una nuova strategia per bloccare le cellule tumorali "sul posto"

Nuove cure contro i tumori, ma è rebus sugli effetti collaterali - Focus Tumore news - Ansa.it

Combat Medical Highlights Patient Impact of HIVEC HEAT Trial at the American Urological Association Annual Meeting

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Approach significantly improved local control, and longer survival observed in trial

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living…

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common…

CHICAGO — The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they…

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit